À¶Ý®ÊÓƵ

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
À¶Ý®ÊÓƵ

TREATMENT OF HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA WITH LIVER-TRANSPLANTATION

À¶Ý®ÊÓƵ

TREATMENT OF HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA WITH LIVER-TRANSPLANTATION CANCER Marino, I. R., Todo, S., Tzakis, A. G., Klintmalm, G., Kelleher, M., Iwatsuki, S., Starzl, T. E., Esquivel, C. O. 1988; 62 (10): 2079-2084

Abstract

Ten patients received liver transplants for unresectable epithelioid hemangioendothelioma (EHE). At the time of transplantation, four patients had microscopic metastases to the hilar lymph nodes, and one of the four also had metastases to a rib. The fifth patient had metastases to the lung, pleura, and diaphragm. The remaining five patients were believed to be free of metastatic disease. Two of these five patients died of metastatic disease at 3 and 16 months, respectively, after transplantation. Interestingly, all five patients with metastatic involvement are currently alive 40.6 +/- 22 months (mean +/- standard error of mean [SEM]) after transplantation, although one of these patients currently has metastatic disease to the lungs and mediastinum. Thus, the projected 5-year actuarial survival rate is 76%, with two patients at risk after the third year. In conclusion, liver transplantation is a reasonable procedure for bulky, otherwise unresectable, EHE even in the presence of metastatic disease.

View details for

View details for

View details for